Publication
  • ERA •
  • 4 June, 2026 •
  • •

Epidemiology of C3G and primary IC-MPGN: a systematic literature review and meta-analysis

Fernando Caravaca-Fontán, Carly Rich, Veruska Carboni, Jameel Nazir, Chris D Poole, Daniel P Gale

Publication
  • ERA •
  • 4 June, 2026 •
  • •

Pegcetacoplan sustained clinical benefit in C3G and primary IC-MPGN through 1 year of therapy: Data from VALIANT/VALE

Fadi Fakhouri, Gema Ariceta, Matthew C Pickering, Moglie Le Quintrec, Marina Vivarelli, Carla M Nester, Bradley P Dixon, Virginia Taliadouros, Johan Szamosi, Kathryn Gordon, Anwesha Mukherjee, Christoph Licht

Publication
  • ERA •
  • 4 June, 2026 •
  • •

Safety and low incidence of meningococcal infections with pegcetacoplan in C3G / primary IC-MPGN and PNH

Antonio Mastrangelo, Daniel P Gale, Daniel Zecher, Nabil Melhem, Sanya Norouzi, Bradley P Dixon, Sheena Patel, Liza Alkhori Franzén, Gashu Ayehu, Chauncey Clemons, Régis Peffault de Latour

Publication
  • WCN •
  • 20 March, 2026 •
  • •

Efficacy of pegcetacoplan in patients with lower baseline proteinuria: A subgroup analysis from the VALIANT trial

Seung Hyeok Han, Hee Gyung Kang, Nicholas Webb, Johan Szamosi, Regina Horneff, Yiwei Zhang, Eli Khankin, Carla M Nester

Available materials

Poster
Publication
  • WCN •
  • 20 March, 2026 •
  • •

Clinical Efficacy Of Pegcetacoplan Versus Iptacopan In Patients With C3 Glomerulopathy: Indirect Treatment Comparison

Bradley P Dixon, Andrew S Bomback, Carly Rich, Mingyi Huang, Piotr Wojciechowski, Rose Chang, Fernardo Caravaca-Fontán, Fadi Fakhouri

Available materials

Poster
Publication
  • ASCPT •
  • 5 March, 2026 •
  • •

Pegcetacoplan population pharmacokinetic and exposure-response in pediatric and adult patients with C3G and primary immune-complex membranoproliferative glomerulonephritis

Ali Keshavarz, Priska Kaufmann, Brandon Smith, Xiaoying Yu, Sravan Karumanchi, Ryan L Crass

Available materials

Poster
Publication
  • ASN •
  • 8 November, 2025 •
  • •

Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial

Carla M Nester, Fadi Fakhouri, Daniel P Gale, Andrew S Bomback, Christoph Licht, Giuseppe Remuzzi, Nicole CAJ Van de Kar, Katie Gordon, Anwesha Mukherjee, Johan Szamosi, Lucía Quintana-Gallardo, Matthew C Pickering

Available materials

Oral Presentation
Sign up for alerts